Report Highlights

UK Occlusion Devices: Market Overview

The UK occlusion devices market was valued at £312 million in 2024, structured across three principal clinical segments: cardiac occlusion (led by atrial septal defect and PFO closure devices), peripheral vascular occlusion (embolisation coils, plugs, and liquid embolic agents), and neurovascular occlusion (flow diverters and intrasaccular devices for aneurysm treatment). The National Health Service functions as the dominant procurement authority, channelling the majority of device purchases through NHS Supply Chain's Category Tower for Surgical and Interventional products. Private hospital groups, including HCA Healthcare UK and Spire Health, account for an estimated 18% of volume, largely in elective cardiac procedures.

Government commissioning policy has been the single most influential force shaping the market's current structure. NHS England's Specialised Commissioning function determines which occlusion procedures receive national funding, and its clinical policies directly govern device eligibility and procedural volumes at trust level. The Cardiovascular Disease National Ambitions Framework, published in 2023, committed to reducing premature cardiovascular mortality by 25% by 2028, which has translated into expanded catheter laboratory capacity and accelerated device procurement across the country's 82 designated cardiac centres, embedding occlusion devices firmly within NHS capital planning cycles.

Policy-Driven Growth in UK Occlusion Devices

Three specific policy mechanisms are generating measurable demand growth. First, NHS England's Commissioning Policy NHSCB/CP/13/P, updated in 2022, formally authorised transcatheter PFO closure as a routinely commissioned procedure for patients with prior cryptogenic stroke under 60 years of age, removing the prior exceptional funding barrier. This reclassification directly increased the eligible patient pool by an estimated 9,000 procedures annually and has driven sustained single-digit annual unit volume growth across implanting centres. The policy mandates referral through designated neurology and cardiology multidisciplinary teams, concentrating procurement within NHS foundation trusts with established catheter laboratory infrastructure.

Second, the NHS Long Term Plan's commitment to expanding structural heart disease interventions has been operationalised through the Getting It Right First Time (GIRFT) Cardiac Surgery report, which explicitly benchmarked transcatheter closure rates against European peers and identified underperformance at regional level. GIRFT recommendations carry effective compliance weight within NHS England's operational planning framework. Third, NICE Technology Appraisal TA566, covering left atrial appendage occlusion devices for patients with non-valvular atrial fibrillation contraindicated for anticoagulation, created a nationally funded pathway for Watchman FLX and Amulet devices, generating an estimated additional £22 million in annual device spend since its 2019 implementation.

Regulatory Barriers and Compliance Costs

The principal regulatory barrier for occlusion device manufacturers operating in the UK is MHRA's device approval framework under the Medical Devices Regulations 2002 (as amended by the Medical Devices (Amendment) (EU Exit) Regulations 2019). The MHRA extended recognition of CE marks issued under EU MDR 2017/745 until 30 June 2030, but new devices entering the market after July 2023 require UKCA marking supported by a UK Approved Body conformity assessment. Only three UK Approved Bodies currently hold designation for Class III implantable devices — BSI, SGS United Kingdom, and UL International — creating a significant bottleneck. Assessment timelines for novel occlusion devices run between 18 and 30 months, during which market entry is effectively blocked regardless of existing CE approval status in the EU.

NHS England's Clinical Commissioning Policies impose a second layer of compliance burden distinct from MHRA registration. Devices must be named within an active commissioned policy or receive Individual Funding Request approval on a per-patient basis, a process administered by integrated care boards that averages 12 weeks per case. Local content rules do not apply formally, but NHS Supply Chain's framework agreements favour suppliers meeting NHS Net Zero Carbon Footprint Plus requirements under the Greener NHS programme, with device packaging and logistics carbon data now required as part of tender submissions. Failure to provide this data results in scoring penalties during competitive procurement evaluation conducted under the Public Contracts Regulations 2015.

Policy-Created Opportunities in UK Occlusion Devices

The MHRA's Innovative Licensing and Access Pathway (ILAP), introduced in 2021 and expanded in scope in 2024, offers a structured mechanism for novel occlusion devices to receive early MHRA scientific advice, accelerating conformity assessment preparation. Devices targeting unmet cardiovascular needs — including left atrial appendage occluders for renal-impaired patients and biodegradable peripheral vascular plugs — are eligible for an ILAP Target Development Profile that coordinates MHRA, NICE, and NHS England engagement in parallel, reducing the typical 36-month market access timeline by an estimated 9 to 12 months. This represents a concrete regulatory incentive for manufacturers developing next-generation closure technologies to enter the UK ahead of EU access timelines currently constrained by notified body capacity shortfalls.

A second major opportunity arises from NHS England's Elective Recovery Fund, through which integrated care systems received £700 million in 2023–24 specifically to address cardiovascular procedure backlogs accumulated during the COVID-19 pandemic. Cardiac catheter laboratory utilisation data published by NHS England in 2024 shows that structural heart procedure volumes remain 11% below pre-pandemic trajectory, creating direct incremental demand for septal occluders and LAA closure devices. Additionally, the NHS Accelerated Access Collaborative's MedTech Funding Mandate, which requires ICBs to fund NICE-recommended devices within three months of a positive Medtech Innovation Briefing, provides a time-bound procurement guarantee for any occlusion device achieving a favourable NICE MIB recommendation during the forecast period.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic plc
• Occlutech International
• W. L. Gore and Associates
• Penumbra Inc.
• Stryker Corporation
• Terumo Corporation
• Cook Medical
• Lepu Medical Technology

Regulatory and Policy Environment

The primary legislative instrument governing occlusion devices in the UK is the Medical Devices Regulations 2002 (SI 2002/618), substantially amended by the Medical Devices (Amendment) (EU Exit) Regulations 2019 to establish the MHRA as the sovereign competent authority post-Brexit. Class III implantable occlusion devices — including cardiac septal occluders, LAA closure devices, and intracranial flow diverters — are subject to the most rigorous conformity assessment pathway, requiring pre-market notification under Regulation 60 and mandatory post-market clinical follow-up submitted to the MHRA's EUDAMED successor database, the UK Device Registration System (UKDRS), operational from January 2025. The MHRA published its revised post-market surveillance guidance in March 2024, requiring manufacturers to submit Periodic Safety Update Reports every two years for Class III devices, with first submissions due by December 2025 for devices registered prior to 2023. Compared to regional peers, the UK framework is now running on an independent trajectory: Irish and EU-registered devices operate under EU MDR with EMA coordination, while the UK requires separate Approved Body certification, creating duplicated regulatory pathways for manufacturers serving both markets.

NICE's role in the occlusion devices policy environment is functionally equivalent to a secondary regulator. Its Medical Technologies Evaluation Programme and Technology Appraisal processes determine clinical and economic evidence thresholds that device manufacturers must meet to achieve NHS commissioning eligibility. Upcoming regulatory milestones include the MHRA's planned consultation on domestic Clinical Investigation requirements for novel implantable devices, expected in Q3 2025, which may introduce UK-specific trial data requirements beyond those accepted from EU or US regulatory submissions. The NHS England Specialised Commissioning review of structural heart disease interventions, anticipated in 2026, is expected to expand the PFO closure age threshold from 60 to 65 years, directly enlarging the commissioning-eligible patient population and creating a material step-change in annual procurement volumes.

Long-Term Policy Outlook for UK Occlusion Devices

By 2032, the UK regulatory landscape for occlusion devices will be fully decoupled from the EU MDR framework, with UKCA marking mandatory for all new and renewed device registrations following the expiry of CE mark recognition on 30 June 2030. The MHRA's ambition, stated in its 2021 discussion paper "The Future Regulation of Medical Devices in the United Kingdom," is to develop a global comparator recognition scheme allowing devices approved by the FDA, Health Canada, or the Therapeutic Goods Administration to access a streamlined UK pathway. If implemented before 2030, this would significantly reduce entry barriers for US-origin occlusion technologies and intensify competitive pressure on European incumbents currently benefiting from legacy CE-to-UKCA grandfathering arrangements.

NHS structural reforms under the Health and Care Act 2022, which established 42 integrated care systems as the operational commissioning units, will progressively shift procurement leverage toward regional ICB consortia capable of negotiating volume-based device contracts independently of central NHS Supply Chain frameworks. By 2028, at least 12 ICBs covering high-density cardiovascular population clusters — including Greater Manchester, West Yorkshire, and the South East London ICS — are expected to establish their own structural heart disease procurement groups, creating differentiated regional pricing environments. Manufacturers that align early with ICB-level clinical pathway development, rather than relying exclusively on national commissioning policy, will secure durable market positions through the end of the forecast period.